Compare CATO & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CATO | NOTV |
|---|---|---|
| Founded | 1946 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.5M | 29.9M |
| IPO Year | N/A | 1997 |
| Metric | CATO | NOTV |
|---|---|---|
| Price | $3.20 | $0.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 53.9K | ★ 1.6M |
| Earning Date | 11-20-2025 | 12-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $660,062,000.00 | $513,024,000.00 |
| Revenue This Year | N/A | $6.26 |
| Revenue Next Year | N/A | $45.49 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 4.54 |
| 52 Week Low | $2.19 | $0.66 |
| 52 Week High | $4.92 | $6.48 |
| Indicator | CATO | NOTV |
|---|---|---|
| Relative Strength Index (RSI) | 37.97 | 38.71 |
| Support Level | $3.28 | $0.79 |
| Resistance Level | $3.60 | $0.95 |
| Average True Range (ATR) | 0.18 | 0.08 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 25.63 | 33.30 |
The Cato Corp operates as a specialty retailer of fashion apparel and accessories in the southeastern United States. Its primary objective is to be the fashion specialty retailer for fashion and value in its markets. The company operates through the following business segments: Retail and Credit. The Retail segment which generates the majority of revenue offers fashion specialty stores. The Credit segment involves credit card services.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.